AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NICE 'too quick to block new drugs'.(National Institute for Health and Clinical Excellence)
Economists warn NICE may be ill-prepared for value-based pricing plan.
NICE too readily blocks access to new drugs and lacks research expertise needed to support value-based pricing, health economists have argued.
A report by the University of York's Centre for Health Economics (CHE) said NICE underuses the option of backing a drug's use 'only in research'.
NICE currently has at least four options when assessing new technologies: reject, approve, approve only in research and approve with research. But NICE rarely recommends approval only in research or with research, the CHE said.
When value-based pricing is introduced, restricted approvals will …
-
- Safeguarding the future of the NHS.
-
News wire article from: Europe Intelligence Wire
June 20, 2011
700+ words
-
- Reform of System for Approving NHS Drugs Taking Too Long, Say MPs
-
News wire article from: Europe Intelligence Wire
January 16, 2013
700+ words
-
- Patients to benefit from new drug pricing system.
-
News wire article from: Europe Intelligence Wire
December 16, 2010
700+ words
-
- E-WORLD: 'Iceberg' in software rollouts.
-
News wire article from: Business Line
July 12, 2010
700+ words
-
- Prime Minister approves plan to devise cotton cess formula.
-
Magazine article from: Business Recorder
August 5, 2006
700+ words
